Definitive Contract 75D30124C00057

Award Date 8/19/24
Potential Completion Date 8/12/29
Potential Value $249K
Federal Agency
CDC Pittsburgh
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Atlanta, GA 30329, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $92,772.80 firm-fixed-price purchase order contract to Luminex Corporation, a manufacturer of biological testing technologies and diagnostic solutions. The contract does not have a set-aside designation. Luminex has previously provided immunology services, laboratory supplies, reagents, multiplexing equipment, maintenance, and diagnostic testing products to various federal agencies, including the CDC, Department of Veterans...
The Centers for Disease Control and Prevention (CDC) awarded Luminex Corporation a $101,651.60 purchase order contract for laboratory supplies. The contract has a period of performance from September 21, 2023 through November 1, 2024. Luminex will provide the supplies to support CDC programs in Pittsburgh, Pennsylvania on a firm fixed price basis. No subcontractors or set aside designations were identified. The CDC works to protect public health and safety through the control and prevention of...
The Centers for Disease Control and Prevention (CDC) awarded a $79,711 firm-fixed-price purchase order contract to Luminex Corporation for annual services. The contract has an ultimate completion date of April 30, 2026. Luminex is a manufacturer of biological testing technologies, including multiplex diagnostic solutions, and often serves as a prime contractor delivering specialized multiplexing systems to federal agencies. This contract is not designated as a set-aside requirement. Luminex...
This is a $7,717 firm fixed price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) in Pittsburgh to Luminex Corporation, a manufacturer of biological testing technologies. The contract is for the provision of a LUMINEX 200 service and does not have a set-aside designation. Luminex often serves as a prime contractor delivering specialized multiplexing systems that support clinical testing programs and biomedical research efforts across federal agencies,...
This federal contract award is for a LUMINEX GUAVA SYSTEM, valued at $94,312.30, and was issued by the Centers for Disease Control and Prevention (CDC) in Pittsburgh, PA. The contract was awarded to Luminex Corporation, a manufacturer of biological testing technologies, including multiplex diagnostic solutions for clinical laboratories and life science research settings. The contract is a firm fixed-price purchase order and is not a set-aside. Luminex has provided various diagnostic testing...
This is a $97,636.38 firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Luminex Corp, a manufacturer of biological testing technologies including multiplex diagnostic solutions. The contract is for the provision of lab supplies, and is not set aside. Luminex has previously provided the CDC, as well as other federal agencies like the Department of Veterans Affairs and Department of Defense, with immunology services, laboratory supplies,...
This is a $20,791.54 firm-fixed price purchase order awarded to Luminex Corp, a foreign-owned, for-profit manufacturer of biological testing technologies. The contract is for the delivery of MICROSPHERE, MAGPLEXAVIDIN, REG 026, 1ML to the Centers for Disease Control and Prevention (CDC) in Pittsburgh. The contract has a completion date of September 30, 2024 and was awarded on September 12, 2024. There is no set-aside designation for this award. Luminex has provided various diagnostic testing...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $241,355.50 firm fixed price purchase order to Luminex Corporation, a foreign-owned for-profit manufacturer of biological testing technologies. The contract is for the provision of lab supplies, with no set-aside designation, and a completion date of October 1, 2021. Luminex is a provider of proprietary multiplex diagnostic solutions to federal agencies, including the CDC, Department of Veterans...
This is a $23,850 firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Luminex Corporation, a foreign-owned for-profit manufacturer of biological testing technologies. The contract is for the provision of LUMINEX 200 SERVICE, with a period of performance through July 2027. Luminex Corporation is the prime contractor and holds several significant federal contract vehicles with the USDA and Department of Veterans Affairs for its specialized...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $7,950.00 firm fixed-price purchase order to Luminex Corporation, a foreign-owned for-profit manufacturer of diagnostic technologies, for an annual service contract for Luminex 200 equipment. The contract, which runs through April 29, 2025, does not have a small business set-aside designation. Luminex is an established federal contractor, holding several indefinite delivery vehicles (IDVs) with agencies like the U.S....

This is a $248,758.07 definitive contract award to Luminex Corp, a manufacturer of biological testing technologies, by the Centers for Disease Control and Prevention (CDC) Pittsburgh. The contract is for the purchase of an instrument that can detect multiple analytes without the use of lasers, which require more frequent and expensive calibration. Luminex has provided similar products and services to the CDC and other federal agencies in the past, including immunology services, laboratory supplies, reagents, multiplexing equipment, maintenance, and diagnostic testing products. The contract has no set-aside designation and is a firm-fixed-price award with an ultimate completion date of August 12, 2029.

Generated 8/15/24, 9:28 AM